Related Experiment Video
Updated: Mar 18, 2026
12:33
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
48.7K
[Not Available]
Danièle Bentué-Ferrer1, Olivier Tribut1, Marie-Clémence Verdier1
1Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
Therapie
|July 10, 2016
Summary
Clobazam, an anticonvulsant, has an active metabolite, norclobazam, with a longer half-life. Therapeutic drug monitoring for clobazam is considered largely ineffective due to complex factors.
Area of Science:
- Pharmacology
- Clinical Pharmacy
Context:
- Clobazam is a 1,5-benzodiazepine used as adjunctive therapy for refractory epilepsies and adult anxiety.
- It is metabolized into an active metabolite, norclobazam, with significantly higher plasma concentrations and a longer elimination half-life than the parent drug.
Purpose:
- To evaluate the utility of therapeutic drug monitoring (TDM) for clobazam and its active metabolite, norclobazam.
- To understand the pharmacokinetic and pharmacodynamic complexities influencing clobazam efficacy and safety.
Summary:
- Clobazam exhibits substantial inter-individual variability in plasma concentrations.
- The concentration-effect relationship is challenging to establish due to add-on therapy and dose-response complexities.
- Adverse reactions and tolerance are more frequent at higher concentrations, but TDM is deemed 'rather useless' due to lack of validated therapeutic ranges and kinetic interactions.
Impact:
- Highlights the challenges in optimizing clobazam therapy due to its complex pharmacokinetics and metabolism.
- Suggests that current evidence does not support routine therapeutic drug monitoring for clobazam.
- Underscores the need for further research to establish clear guidelines for clobazam dosing and monitoring.
